Allogene Therapeutics, Inc. financial data

Symbol
ALLO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
210 East Grand Avenue, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.25K % +29.6%
Debt-to-equity 25.1 % +7.16%
Return On Equity -54 % +1.78%
Return On Assets -43.2 % +3.1%
Operating Margin -445K % -30.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 209M shares +24.7%
Common Stock, Shares, Outstanding 209M shares +25.1%
Entity Public Float 557M USD -44.8%
Common Stock, Value, Issued 209K USD +25.2%
Weighted Average Number of Shares Outstanding, Basic 190M shares +29.5%
Weighted Average Number of Shares Outstanding, Diluted 190M shares +29.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 65K USD -38.1%
Research and Development Expense 203M USD -27.8%
General and Administrative Expense 67.6M USD -12.5%
Operating Income (Loss) -289M USD +19.4%
Nonoperating Income (Expense) 9.62M USD +288%
Net Income (Loss) Attributable to Parent -279M USD +22.5%
Earnings Per Share, Basic -1.59 USD/shares +36.1%
Earnings Per Share, Diluted -1.59 USD/shares +36.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 171M USD +10.3%
Cash, Cash Equivalents, and Short-term Investments 445M USD -18.3%
Assets, Current 457M USD -8.96%
Property, Plant and Equipment, Net 92.1M USD -13.4%
Operating Lease, Right-of-Use Asset 58.4M USD -27.3%
Other Assets, Noncurrent 6.44M USD -31.4%
Assets 647M USD -16.3%
Accounts Payable, Current 12.9M USD +26.5%
Employee-related Liabilities, Current 12.7M USD -29.4%
Contract with Customer, Liability, Current 86K USD 0%
Liabilities, Current 37.3M USD -31.6%
Operating Lease, Liability, Noncurrent 87M USD -5.26%
Other Liabilities, Noncurrent 7.55M USD +45.3%
Liabilities 132M USD -13%
Accumulated Other Comprehensive Income (Loss), Net of Tax -780K USD +79.7%
Retained Earnings (Accumulated Deficit) -1.69B USD -19.8%
Stockholders' Equity Attributable to Parent 515M USD -17.1%
Liabilities and Equity 647M USD -16.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -55.9M USD +16.1%
Net Cash Provided by (Used in) Financing Activities 1.65M USD -4.68%
Net Cash Provided by (Used in) Investing Activities 22.1M USD -80.4%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 209M shares +25.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -32.1M USD -167%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 181M USD +9.64%
Deferred Tax Assets, Valuation Allowance 400M USD +25%
Deferred Tax Assets, Gross 418M USD +21.7%
Operating Lease, Liability 94.2M USD -4.07%
Depreciation 3.56M USD +1.37%
Payments to Acquire Property, Plant, and Equipment 1.04M USD -45.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -276M USD +21.7%
Lessee, Operating Lease, Liability, to be Paid 126M USD -6.62%
Property, Plant and Equipment, Gross 148M USD -1.32%
Operating Lease, Liability, Current 7.22M USD +13.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13.2M USD +4.25%
Lessee, Operating Lease, Liability, to be Paid, Year One 12.9M USD +3.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure -14.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 31.3M USD -13.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 13.6M USD +6.19%
Deferred Tax Assets, Operating Loss Carryforwards 211M USD +21.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 18.9M USD +29.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 14.1M USD +6.18%
Operating Lease, Payments 3.1M USD +3.33%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 60.8M USD -24.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%